BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
March 22, 2022 05:00 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
NOBLEGEN_CMYK_Plum copy.png
Noblegen adds Craig Cogut and Dr. Rajiv Shah to its Board of Directors and opens its Series C capital raise with a $500M target
July 06, 2021 08:00 ET | Noblegen
PETERBOROUGH, Ontario, July 06, 2021 (GLOBE NEWSWIRE) -- Noblegen Inc. (“Noblegen"), an advanced digital biology company, is excited to announce that Craig Cogut, the Founder, Chairman, and CEO of...
logo.jpg
Ault Life Sciences Launches $100 Million 506(c) and Regulation S Offering
May 07, 2020 07:00 ET | Ault Life Sciences, Inc.
NEWPORT BEACH, Calif., May 07, 2020 (GLOBE NEWSWIRE) --  Ault Life Sciences, Inc. (“ALSI” or the “Company”), a Delaware corporation, announced that it is seeking to raise up to $100 million through...
Dr. Shytle
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
October 29, 2018 09:00 ET | Alzamend Neuro, Inc.
Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”)...